{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:52:51Z","timestamp":1777024371503,"version":"3.51.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26 March 2022. Only randomized controlled trials (RCTs) that evaluated delafloxacin and comparator antibiotics for treating acute bacterial infections in adult patients were included. The clinical cure rate and microbiological eradication rate at the posttreatment evaluation, while the secondary outcomes included the risk of adverse events (AEs).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, six randomized controlled trials (RCTs) involving 3,019 patients with acute bacterial infection were included. There were no significant differences in the clinical cure rate between delafloxacin and comparators (OR = 1.06%, 95% CI = 0.89\u20131.26, I<jats:sup>2<\/jats:sup> = 0%). Overall, the results showed that delafloxacin had a microbiological eradication rate (documented and presumed) similar to the comparators (OR = 1.33%, 95% CI = 0.94\u20131.88, I<jats:sup>2<\/jats:sup> = 0%) in the pooled analysis of the six studies. Any treatment-emergent adverse events (TEAEs) did not show significant differences between delafloxacin and the comparators (OR = 0.93%, 95% CI = 0.80\u20131.08, I<jats:sup>2<\/jats:sup> = 75%). Serious adverse events (SAEs) did not differ between the delafloxacin and comparators (OR = 0.94%, 95% CI = 0.67\u20131.32, I<jats:sup>2<\/jats:sup> = 0%). The results of gastrointestinal disorders were (OR = 1.26%, 95% CI = 1.01\u20131.56, I<jats:sup>2<\/jats:sup> = 89%), and nausea, vomiting, and diarrhea were (OR = 0.77%, 95% CI = 0.45\u20131.34, I<jats:sup>2<\/jats:sup> = 79%), (OR = 1.00%, 95% CI = 0.74\u20131.36, I<jats:sup>2<\/jats:sup> = 72%), and (OR = 2.10%, 95% CI = 1.70\u20132.96, I<jats:sup>2<\/jats:sup> = 0%), respectively. The results showed that there was no significant difference in the incidence of nausea and vomiting between delafloxacin and the comparator, but the incidence of diarrhea was higher. The analysis of neurological disorders indicated that the incidence of nervous system disorders was lower in the delafloxacin group (OR = 0.71%, 95% CI = 0.50\u20131.01, I<jats:sup>2<\/jats:sup> = 52%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The clinical efficacy, microbiological eradication rate and the incidence of AEs of delafloxacin in the treatment of acute bacterial infections were similar to those of the comparators, as an alternative therapeutic agent.<\/jats:p>","DOI":"10.3389\/fphar.2022.975578","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T06:07:53Z","timestamp":1664345273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Rong","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1093\/cid\/ciy1080","article-title":"Analysis of pooled phase 3 safety data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Bassetti","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"E5662","DOI":"10.3390\/molecules25235662","article-title":"Quinolones: Mechanism, lethality and their contributions to antibiotic resistance","volume":"25","author":"Bush","year":"2020","journal-title":"Molecules"},{"key":"B3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of quinolone action and resistance: Where do we stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1093\/cid\/ciz006","article-title":"Analysis of pooled phase III efficacy data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Giordano","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B6","doi-asserted-by":"publisher","first-page":"ofz514","DOI":"10.1093\/ofid\/ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: Place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/antibiotics10121506","article-title":"Delafloxacin, finafloxacin, and zabofloxacin: Novel fluoroquinolones in the antibiotic pipeline","volume":"10","author":"Kocsis","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2147\/IDR.S202160","article-title":"Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Lan","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"B11","doi-asserted-by":"publisher","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","article-title":"Safety of delafloxacin: Focus on adverse events of special interest","volume":"5","author":"Lodise","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-017-0790-5","article-title":"Delafloxacin: First global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e00772","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijid.2020.06.018","article-title":"Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial","volume":"97","author":"McCurdy","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: A phase 3, multinational, double-blind, randomized study","volume":"67","author":"O'Riordan","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O'Riordan","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: A phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: A review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of delafloxacin","volume":"44","author":"Shiu","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/cid\/ciy1079","article-title":"Profile of a novel anionic fluoroquinolone-delafloxacin","volume":"68","author":"Tulkens","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review","volume":"41","author":"Yaghoubi","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.975578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T06:07:55Z","timestamp":1664345275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.975578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":21,"alternative-id":["10.3389\/fphar.2022.975578"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.975578","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"article-number":"975578"}}